Le Lézard
Classified in: Health
Subjects: CALENDAR OF EVENTS, HEALTH, LIFESTYLE, MISCELLANEOUS, MISCELLANEOUS

ANTIBIOTICS AWARENESS WEEK


Montreal, Nov. 07, 2018 (GLOBE NEWSWIRE) --
Echinacea can successfully prevent respiratory tract infections and related complications in children, reducing the need for antibiotics by almost 73 per cent

 

As the need to decrease the use of antibiotics grows more urgent, results from the largest clinical trial on the preventive use of Echinacea in children reveal an effective alternative for cold and flu season. The study showed supplements containing fresh Echinacea purpurea can successfully prevent respiratory tract infections and related complications, reducing the need for antibiotics by almost 73 per cent1.

 

Respiratory tract infections like colds and flu are the most frequent reason for antibiotic prescriptions worldwide.2 Although viral, these infections tend to develop into bacterial conditions, associated with pneumonia, sinusitis or bronchitis so many physicians prescribe antibiotics to keep these infections at bay. Every year, over 25 million antibiotic prescriptions are written for human consumption in Canada, 30 to 50 per cent of which are estimated to be unnecessary.3 This use and overuse of antibiotics is causing a rise in antibiotic resistant bacteria and infections.

 

"Antibiotic over-use is particularly serious in children. Children typically get six to eight respiratory tract infections annually. As these infections have an average complication rate of 30 per cent, children are being prescribed antibiotics one to two times annually," says pharmacist Sherry Torkos. "Anyone can get an antibiotic-resistant infection. However, young children's immune systems aren't developed so they are more susceptible to infection and these infections are more likely to have a serious impact on their health."

 

Led by researchers with A. Vogel Bioforce, the controlled, randomized, blind, multicentre clinical study was designed to evaluate the efficacy and safety of Echinacea to prevent colds and flus, reduce secondary complications and, as a result, the need for antibiotics. Conducted in Switzerland between 2016 and 2017, the trial involved 203 children aged four to twelve-years-old, and 13 pediatricians. The children received Echinaforce® Junior tablets daily over a period of four months. The control group received low-dose vitamin C. Key findings include:

 

 

The World Health Organization (WHO) strongly recommends a reduction of antibiotic usage as antibiotics are significantly contributing to the increase in multi-resistant bacteria. "Echinacea will not replace antibiotics, which are a tremendously important substance class for the acute treatment of life-threatening diseases," says Dr Andy Suter, Head of Research and Development at A. Vogel Bioforce AG.  "Nevertheless, with Echinacea we may be able to use this highly valuable medicine less frequently and more specifically in the future."

 

About A. Vogel Bioforce AG

A. Vogel Bioforce's mission is to help people maintain or regain health naturally. Based on the lifelong work of Swiss natural health pioneer Alfred Vogel, Bioforce Canada is the premier supplier of high quality natural products in Canada. Its products are manufactured in Switzerland and distributed to more than 25 countries. For more information, visit www.avogel.ca

 

###

 

To schedule an interview with pharmacist Sherry Torkos, please contact: Katherine Clark, Cowan & Company, 416-462-8773 ext. 55 or [email protected]        

 

 



1 Ogal M, Klein P, Schoop R. Echinacea for the Prevention of Respiratory Tract Infections in Children   4 ? 12 years: A Randomized, Blind and Controlled Study. Sociéte Suisse de Pédiatrie (SSP, Poster), 24th May, Lausanne, Switzerland.

2 Nyquist AC, Gonzales R, Steiner JF, Sande MA. Antibiotic prescribing for children with colds, upper   respiratory tract infections, and bronchitis. JAMA. 1998;279(11):875-7.

3  https://choosingwiselycanada.org/campaign/antibiotics/


These press releases may also interest you

at 07:45
Microbix Biosystems Inc. , a life sciences innovator, manufacturer, and exporter, reports results for its second quarter and first half of fiscal 2024 ended March 31, 2024 ("Q2" and "H1"), with strong growth in sequential and year-over-year quarterly...

at 07:35
Vektor Medical, a pioneer in non-invasive, AI-based arrhythmia analysis technology, today unveiled a comprehensive schedule of educational content and sessions featuring the use of vMap® at this year's Heart Rhythm 2024 conference in Boston, May...

at 07:30
Positive Phase 3 PL9643 MELODY-1 Pivotal Study ResultsCo-Primary Symptom Endpoint of Pain Met Statistical Significance (P<0.025) and 7 of 11 Secondary Symptom Endpoints Met Statistical Significance (P<0.05), at the12-Week Treatment PeriodRapid...

at 07:30
The Foundation Fighting Blindness, the driving force in the global development of treatments and cures for blinding diseases, announces today its partnership with PreventionGenetics, a part of Exact Sciences, as its new genetic laboratory partner for...

at 07:30
Spyre Therapeutics, Inc. (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches for the treatment of Inflammatory Bowel...

at 07:30
The shareholders of Calliditas Therapeutics AB (publ) ("Calliditas Therapeutics"), Reg. No. 556659-9766, with registered office in Stockholm, are summoned to the annual general meeting on Monday 17 June 2024 at 2.00 p.m. CEST at Klara,...



News published on and distributed by: